198 related articles for article (PubMed ID: 19074062)
1. New advances in the pathogenesis and therapy of essential thrombocythemia.
Levine RL; Heaney M
Hematology Am Soc Hematol Educ Program; 2008; ():76-82. PubMed ID: 19074062
[TBL] [Abstract][Full Text] [Related]
2. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
3. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
4. Thrombocytosis.
Skoda RC
Hematology Am Soc Hematol Educ Program; 2009; ():159-67. PubMed ID: 20008195
[TBL] [Abstract][Full Text] [Related]
5. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
6. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
7. JAK and MPL mutations in myeloid malignancies.
Tefferi A
Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
9. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.
Cabagnols X; Favale F; Pasquier F; Messaoudi K; Defour JP; Ianotto JC; Marzac C; Le Couédic JP; Droin N; Chachoua I; Favier R; Diop MK; Ugo V; Casadevall N; Debili N; Raslova H; Bellanné-Chantelot C; Constantinescu SN; Bluteau O; Plo I; Vainchenker W
Blood; 2016 Jan; 127(3):333-42. PubMed ID: 26450985
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.
Okabe M; Yamaguchi H; Usuki K; Kobayashi Y; Kawata E; Kuroda J; Kimura S; Tajika K; Gomi S; Arima N; Mori S; Ito S; Koizumi M; Ito Y; Wakita S; Arai K; Kitano T; Kosaka F; Dan K; Inokuchi K
Leuk Res; 2016 Jan; 40():68-76. PubMed ID: 26614694
[TBL] [Abstract][Full Text] [Related]
11. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
12. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.
Kawamata N; Ogawa S; Yamamoto G; Lehmann S; Levine RL; Pikman Y; Nannya Y; Sanada M; Miller CW; Gilliland DG; Koeffler HP
Exp Hematol; 2008 Nov; 36(11):1471-9. PubMed ID: 18723266
[TBL] [Abstract][Full Text] [Related]
13. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
14. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
15. Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
Millecker L; Lennon PA; Verstovsek S; Barkoh B; Galbincea J; Hu P; Chen SS; Jones D
Cancer Genet Cytogenet; 2010 Feb; 197(1):1-7. PubMed ID: 20113830
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
17. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
[TBL] [Abstract][Full Text] [Related]
18. Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Stockklausner C; Duffert CM; Cario H; Knöfler R; Streif W; Kulozik AE;
Ann Hematol; 2021 Jul; 100(7):1647-1665. PubMed ID: 33712866
[TBL] [Abstract][Full Text] [Related]
19. Genetic complexity of myeloproliferative neoplasms.
Kralovics R
Leukemia; 2008 Oct; 22(10):1841-8. PubMed ID: 18754034
[TBL] [Abstract][Full Text] [Related]
20. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]